MacroGenics (MGNX) Stock: Buy, Sell, or Hold?
MGNX - MacroGenics, Inc.
$2.25
-1.38 (-38.02%)
▼
5d:
-30.77%
30d:
-40.79%
90d:
-43.75%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 11, 2026
18d
Get Alerted When MGNX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: MGNX is down 30.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: MGNX is down 30.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: MGNX is currently trading at $2.25, which is considered oversold relative to its 30-day fair value range of $3.31 to $4.07.
Technical Outlook: Technically, MGNX is in a downtrend. Immediate support is located at $2.13, while resistance sits at $3.76. Short-term momentum is weak, with the stock down 38.0% recently.
Market Sentiment: MGNX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.00 (+255.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MGNX is in a downtrend. Immediate support is located at $2.13, while resistance sits at $3.76. Short-term momentum is weak, with the stock down 38.0% recently.
Market Sentiment: MGNX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.00 (+255.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.31 -
$4.07
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-38.0%)
- BULLISH: Trading 255.6% below Wall St target ($8.00)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.31 -
$4.07
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.13
Resistance Level
$3.76
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.54
Wall Street Target
$8.00
(+255.6%)
Revenue Growth (YoY)
378.0%
Earnings Growth (YoY)
-70.4%
Profit Margin
-8.3%
Share & Embed Analysis
Last updated: October 23, 2026 6:08 PM ET
Data refreshes hourly during market hours. Next update: 7:08 PM
Data refreshes hourly during market hours. Next update: 7:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MGNX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 59 HOLD |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 64 BUY |
